APA

Wohl D. A., Kendall M. A., Andersen J., Crumpacker C., Spector S. A., Feinberg J., Alston-Smith B., Owens S., Chafey S., Marco M., Maxwell S., Lurain N., Jabs D., Benson C., Keiser P. & Jacobson M. A. (20091015). Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030. : HIV clinical trials.

Chicago

Wohl D A, Kendall M A, Andersen J, Crumpacker C, Spector S A, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Lurain N, Jabs D, Benson C, Keiser P and Jacobson M A. 20091015. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030. : HIV clinical trials.

Harvard

Wohl D. A., Kendall M. A., Andersen J., Crumpacker C., Spector S. A., Feinberg J., Alston-Smith B., Owens S., Chafey S., Marco M., Maxwell S., Lurain N., Jabs D., Benson C., Keiser P. and Jacobson M. A. (20091015). Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030. : HIV clinical trials.

MLA

Wohl D A, Kendall M A, Andersen J, Crumpacker C, Spector S A, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Lurain N, Jabs D, Benson C, Keiser P and Jacobson M A. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030. : HIV clinical trials. 20091015.